Active, not recruitingPhase 2NCT05347212
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
Studying Renal medullary carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Pavlos Msaouel, MD,PHD,PHDM.D. Anderson Cancer Center
- Intervention
- Nivolumab(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (1)
- MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05347212 on ClinicalTrials.gov